13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002011932
Total reported value
$162.1M
$162.1M
53 檔
18.4%
In Q1 2024, Exome Asset Management LLC's U.S. equity holdings reached a combined market value of $162.1M, distributed across 53 disclosed stock positions.
During Q1 2024, Exome Asset Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.46% | +0.72% | — | |
| 2 | RDY | Dr. Reddy's Laboratories-adr | Stock-Other | 5.40% | — | -4.44% | |
| 3 | ONC | Beone Medicines Ltd-adr | Stock-Other | 4.93% | — | +187.50% | |
| 4 | CI | THE Cigna Group | Stock-Healthcare | 4.76% | — | — | |
| 5 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 3.97% | — | -32.56% | |
| 6 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 3.00% | +5.59% | NEW | |
| 7 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.95% | — | — | |
| 8 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 2.95% | -0.07% | — | |
| 9 | DXCM | Dexcom Inc | Stock-Healthcare | 2.95% | — | — | |
| 10 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.66% | — | — | |
| 11 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.56% | — | -36.12% | |
| 12 | GERN | Geron CORP | Stock-Other | 2.51% | +0.49% | NEW | |
| 13 | ✓ | Stock-Other | 2.49% | — | — | ||
| 14 | MOR2 | Morphosys AG Adr | Stock-Other | 2.40% | — | — | |
| 15 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.39% | — | +331.60% | |
| 16 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 2.24% | — | — | |
| 17 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.17% | -0.32% | — | |
| 18 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 2.06% | — | -21.45% | |
| 19 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.81% | — | -40.16% | |
| 20 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.79% | — | — | |
| 21 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.69% | +0.38% | -36.84% | |
| 22 | INSM | Insmed Inc | Stock-Healthcare | 1.67% | -1.34% | +16.59% | |
| 23 | ✓ | Elevation Oncology Inc | Stock-Other | 1.62% | — | — | |
| 24 | EXK | Exact Sciences CORP | Stock-Materials | 1.58% | — | — | |
| 25 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.56% | -0.38% | -25.50% | |
| 26 | RGNX | Regenxbio Inc | Stock-Other | 1.52% | — | — | |
| 27 | BIIB | Biogen Inc | Stock-Healthcare | 1.51% | — | — | |
| 28 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.51% | +1.10% | NEW | |
| 29 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.50% | -0.58% | — | |
| 30 | NTRA | Natera Inc | Stock-Healthcare | 1.46% | +0.38% | — | |
| 31 | PEN | Penumbra Inc | Stock-Healthcare | 1.41% | +0.16% | -14.03% | |
| 32 | GH | Guardant Health Inc | Stock-Healthcare | 1.40% | +2.30% | — | |
| 33 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.39% | — | — | |
| 34 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.36% | +0.14% | — | |
| 35 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.29% | -1.75% | -25.04% | |
| 36 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.28% | — | — | |
| 37 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 1.26% | — | — | |
| 38 | NARIUSD | Inari Medical Inc | Stock-Other | 1.24% | — | — | |
| 39 | QTRX | Quanterix CORP | Stock-Other | 1.20% | — | — | |
| 40 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.20% | — | -28.27% | |
| 41 | SWAVUSD | Shockwave Medical Inc | Stock-Other | 1.12% | — | — | |
| 42 | VYNE | Vyne Therapeutics Inc | Stock-Other | 1.09% | — | +251.76% | |
| 43 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.99% | — | +125.61% | |
| 44 | QTTB | Q32 Bio Inc | Stock-Other | 0.95% | — | — | |
| 45 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 0.90% | — | — | |
| 46 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.87% | -1.32% | — | |
| 47 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.77% | — | — | |
| 48 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.71% | — | — | |
| 49 | NBP | Novabridge Biosciences | Stock-Other | 0.52% | -0.04% | — | |
| 50 | ADAG | Adagene Inc-adr | Stock-Other | 0.37% | -0.22% | — |
According to official SEC Form 13F filings, Exome Asset Management LLC reported a total U.S. public equity portfolio value of $162.1M across 53 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, RDY, ONC) accounted for 18.4% of total reported equity market value during Q1 2024.
During Q1 2024, Exome Asset Management LLC's top holdings by market value included LLY (6.5%)、RDY (5.4%)、ONC (4.9%). The largest single position, LLY, represented 6.5% of total portfolio value.
In Q1 2024, Exome Asset Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.